Macrogenics Inc (NASDAQ:MGNX)
| Market Cap | $125.26M+38.0% |
| Revenue (ttm) | $113.50M-9.9% |
| Net Income | -$51.49M+32.1% |
| EPS | -$0.81+32.5% |
| Shares Out | 63.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,522,923 |
| Open | $1.96 |
| Previous Close | $1.98 |
| Day's Range | $1.95 - $2.08 |
| 52-Week Range | $1.32 - $5.08 |
| Beta | 1.32 |
| Analysts | Buy |
| Price Target | $6.00(+206.12%) |
| Earnings Date | Mar 8, 2027 |
About MGNX
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 8, 2027Earnings report
$MGNX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in MGNX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MGNX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MGNX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New MGNX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MGNX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MGNX
| VTIVanguard Morningstar Total Stock Market ETF | $3.64M |
| IWMiShares Russell 2000 ETF | $3.15M |
| VXFVanguard Extended Market ETF | $1.66M |
| IWOiShares Russell 2000 Growth ETF | $1.03M |
| VFMOVanguard U.S. Momentum Factor ETF | $993.06K |
| VTWOVanguard Russell 2000 ETF | $882.40K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from MGNX’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 earnings miss on revenue with reported loss; concrete negative financial results outweigh any corporate progress highlights.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| CNCR | Loncar Cancer Immunotherapy ETF | 3.17% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.33% |
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.15% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.09% |
| VFMO | Vanguard U.S. Momentum Factor ETF | 0.05% |
| VMO.TO | Vanguard Global Momentum Factor ETF | 0.05% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.03% |
| DUSG | U.S. Small Cap Growth Portfolio: ETF Class Shares | 0.00% |
Weight is the stock’s share of each fund’s holdings.
